We are in indie game developer based out of Oslo, Norway. We have to date launched five games for PC, Switch and mobile platforms. At the moment we develop "Life Below", a creative strategy city-builder where you build and manage ocean ecosystems. So a reef builder! In addition to our own IP, we develop games and gamification projects for society. We call ourselves an impact game developer as many of our projects are focused on positive change to society. Right now we develop a game for all kids going into hospital, a history game to spice up history learning in schools, a city cleaning game using the mascot of Oslo, a climate game and an awareness game tackling difficult issues in relation to sex and identify. Many of our impact projects are successes, and are widely used. Our aim is to make society better, one game at the time.

The way we work has fundamentally changed. In a hybrid world, it’s no longer the office vs. home — it’s both. We believe in the freedom of working anywhere, and that humans thrive when we come together.We believe that work is not a place, it is something you do. Our platform allows companies to deliver a great employee experience by subscribing to office furniture and equipment that transform the office to an inspirational collaboration hub, as well as equipping remote teams with ergonomic home offices — with the click of a button. Our solution is simple, companies subscribe to furniture and equipment with full flexibility. And our asset management system allows for full visibility and control, as well as removing all logistical pains. Our business model is fully circular. This is a win-win, where suppliers keep on owning their assets making a better profit on each product, AND we save the environment by giving all furniture and equipment a longer life! We are a team with a big mission and we are growing! Join the journey.

Unseen Bio™ was founded in 2018 with a vision to increase awareness of the importance of gut health as a means of preventing disease. Our mission is to strengthen the microbiome in order to improve the biodiversity crisis in the gut. Based on a thorough analysis of the microbiome, we provide personal dietary recommendations aimed at increasing biodiversity and improving gut health for the individual. Based on the latest knowledge in the microbiome area and with a focus on preventive healthcare, we are constantly developing our digital platform for intestinal health Digital Gut™.

Our mission is to help food manufacturers reduce food waste and cost through our digital platform. To date, we've successfully transacted over 4.000 tons of food, and we're continuing to scale our business to have an even greater impact. We have ambitious growth plans and are expanding. We recently carried out a rebranding and are in the process of building our product & technology team to scale further.

At Surveypal, we’re reimagining how businesses understand and improve customer experiences through meaningful feedback. Our solutions make it easy for companies to gather, analyze, and act on customer feedback, transforming data into insights that help businesses grow. As we continue to evolve, we're looking for talented pals to join our team. You'll work on cutting-edge solutions that empower businesses to make smarter decisions based on real-time data. We’re a hybrid team passionate about solving problems, learning together, and pushing the boundaries of what’s possible in customer experience management. If you're eager to build software that makes a real difference and enjoy collaborating in an open, supportive environment, Surveypal could be the perfect fit for you. Join us on our mission to make feedback more impactful and be part of shaping the future of customer experience!

Niuton is a deep tech platform that works on autonomous and decentralized solutions based on Newtonian principles and our end customers are hedge funds. Currently, we have a team of five people, the tech dev and research stretches three years back and we have been with one year live with clients. Now we are looking for a senior python specialist to automate the data flow in and out of our core machinery. The data feed into Niutons machinery is from Twelvedata and the output is clients around the world. For the right candidate, we can consider offering 0.5% of shares equity (valuation right now 7.5 million USD), you will be assisted by our other senior python specialist that handles the core machinery itself. The expected duration of this assignment is three to four months ONLY. Start date 1. January 2022. Resources have to be available 100% of the time during the assignment, most preferably in Oslo. The MVP is ready, Niuton is now exactly what we want, and the success criterion is achieving 99% uptime on a day-to-day basis.

Vi er Nolo Nordic og vi gjør alkoholfritt mer spennende, sofistikert, gøy og smakfullt ved å produsere førsteklasses drikkevarer under merkenavnene ALT. og Ambijus. Akkurat nå brygger vi nye nettsider, men besøk gjerne linkene over for å lære mer om våre prisvinnende og kompromissløse alkoholfrie drikker.

50% of the population will encounter mental illness, but 65% leave treatment without results. We're here to change that. We develop the world's first holistic mental healthcare platform designed to improve the effectiveness of psychological treatment. Our SaaS platform for psychologists combines the basic tools needed to administer a private practice, with novel research-based treatment instruments. We are an ambitious team of psychology specialists, business developers, and an advisory board with industry specialists. You can take a look at our team [here](https://www.konfidens.no/team). Mindcare is backed by Innovation Norway, Aleap, and several private investors. We are now hiring our first team members. We're looking for two talented developers to join our company as co-founders and help build the organization and product. Is this you or someone you know? Get in touch!

We digitize our customers by supporting more business processes with software. The core drivers are better insight and higher consistency. We make use of or create new software that solve each prospect. We are profitable and are looking to expand our offering with a modern platform. Voit offers IT systems that make less use of data with experience from everyday life, production and startups.

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

RESPINOR is a privately-owned medical device company, founded in Oslo, 2015. We have developed an objective measure of breathing for critically ill patients within intensive care. The technology provides precise, continuous and real-time information of diaphragm function, our main breathing muscle, to increase the quality of care and reducing costs. RESPINOR’s technology is the winner of Horizon 2020 both in phase I and II. We are addressing an unmet medical need because every breath counts.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Excitus is set up to develop, manufacture and sell medical suction products based on its revolutionary, patent-pending mobile suction platform. Products will span from professional hand-held tools for paramedics to consumer devices in a private home and stored together with the defibrillator at supermarkets, stadiums, etc. The platform enables a higher survival rate at cardiac arrests, yet at the same time, it provides a razor/razorblade business model unseen in this area.

Fishency Innovation can give access to the entire salmon industry to affordable equipment to count automatically sea lice in the cage. Monitoring sea lice is the key to controlling them, it is access to good decision support for optimized treatments and to a reliable tool to measure the efficiency of preventive measures and existing treatments. Today, sea lice are counted manually over 20 fish, every week, in each cage. It is labor-demanding, and the collected data are not reliable. Sustainability starts with good data.

HIGHERED has built the only truly global platform to connect, market, and recruit top talent from graduate schools all over the world. STUDENTS get free access to international jobs to their preferences SCHOOLS get a free self-branded portal for improving career placement and student satisfaction COMPANIES get a cost-effective way to target and recruit top talent from around the world In co-operation with the most acknowledged business school accrediting body in the world, EFMD, Highered has a reach of more than 500 top schools and 3 million students. Global cooperation agreements with companies like Pepsi, UniCredit, Statoil, Accenture, and Yara are in place.